Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator
Carol J Fabian, Bruce F Kimler, Julie Anderson, et al.
The Pharmacogenomics Journal
|
September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
S Yao, L E Sucheston, H Zhao, et al.
Breast Cancer Research and Treatment
|
July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)
Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial
Paul E Goss, James N Ingle, Kathleen I Pritchard, et al.
NPJ Breast Cancer
|
July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
Kerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
The American Journal of Cardiology
|
September 29, 2020
Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer
Muzna Hussain, Yuan Hou, Chris Watson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Pharmacogenetics and Genomics
|
December 27, 2017
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
Lara E Sucheston-Campbell, Alyssa I Clay-Gilmour, William E Barlow, et al.
Breast Cancer Research and Treatment
|
June 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
Judith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator
Carol J Fabian, Bruce F Kimler, Julie Anderson, et al.
The Pharmacogenomics Journal
|
September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
S Yao, L E Sucheston, H Zhao, et al.
Breast Cancer Research and Treatment
|
July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)
Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial
Paul E Goss, James N Ingle, Kathleen I Pritchard, et al.
NPJ Breast Cancer
|
July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
Kerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
The American Journal of Cardiology
|
September 29, 2020
Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer
Muzna Hussain, Yuan Hou, Chris Watson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Pharmacogenetics and Genomics
|
December 27, 2017
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
Lara E Sucheston-Campbell, Alyssa I Clay-Gilmour, William E Barlow, et al.
Breast Cancer Research and Treatment
|
June 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
Judith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Page
of 11